No abstract

No abstract

Objective To evaluate the performance of INTERGROWTH‐21st (IG‐21st) and World Health Organization (WHO) fetal growth charts to identify small‐for‐gestational‐age (SGA) and fetal growth restriction (FGR) neonates, as well as their specific risks for adverse neonatal outcomes. Methods Multicenter cross‐sectional study including 67 968 live births from 10 maternity units across four Latin American countries. According to each standard, neonates were classified as SGA and FGR (birth weight <10th and less than third centiles, respectively). The relative risk (RR) and diagnostic performance for a low APGAR score and low ponderal index were calculated for each standard. Results WHO charts identified more neonates as SGA than IG‐21st (13.9% vs 7%, respectively). Neonates classified as having FGR by both standards had the highest RR for a low APGAR (RR, 5.57 [95% confidence interval (CI), 3.99–7.78]), followed by those who were SGA by both curves (RR, 3.27 [95% CI, 2.52–4.24]), while neonates with SGA identified by WHO alone did not have an additional risk (RR, 0.87 [95% CI, 0.55–1.39]). Furthermore, the diagnostic odds ratio for a low APGAR was higher when IG‐21st was used. Conclusion In a population from Latin America, the WHO charts seem to identify more SGA neonates, but the diagnostic performance of the IG‐21st charts for low APGAR score and low ponderal index is better.

La pandemia de COVID-19 ha generado múltiples interrogantes respecto a su comportamiento en la población gestante y en los resultados perinatales. Los datos disponibles sobre la infección por SARS-CoV-2 en el embarazo son limitados. Se realizó una búsqueda de artículos publicados en las bases de datos PubMed, Scopus y Embase utilizando los términos asociados a COVID-19 y embarazo, hasta el 4 de abril de 2020. En la revisión de 43 artículos se tuvieron en cuenta 25, que corresponden a reportes y series de caso, revisiones y guías de manejo. No se encontró evidencia concluyente respecto a transmisión vertical o a mal resultado perinatal en enfermedad leve o moderada. Los síntomas clínicos de COVID-19 en el embarazo, no varían de los de la población general. Existe controversia en cuanto a lactancia materna. En conclusión, existe escasa evidencia de calidad sobre el efecto de COVID-19 en el embarazo. Dada la ausencia de evidencia concluyente se plantea la realización de un registro nacional de COVID-19 y embarazo para Colombia y la región.